# Integer Holdings Corp: Form 10-Q for the period ended Apr 2, 2010

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2010-05-12
- Accepted by EDGAR: May 12, 2010, 15:47 ET
- Period: 2010-04-02
- Accession: 0000950123-10-048285
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000095012310048285/c00898e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000095012310048285/

## Management's discussion and analysis

As filed, 49,509 characters.

### Our Business

We operate our business in two reportable segments — Greatbatch Medical and Electrochem Solutions (“Electrochem”). Greatbatch Medical designs and manufactures systems, components and devices for the cardiac rhythm management (“CRM”), neuromodulation, vascular and orthopaedics markets. Greatbatch Medical customers include large multi-national original equipment manufacturers (“OEMs”). Greatbatch Medical products include: 1) batteries, capacitors, filtered and unfiltered feedthroughs, engineered components and enclosures used in Implantable Medical Devices (“IMDs”); 2) introducers, catheters, steerable sheaths and implantable stimulation leads; and 3) instruments and delivery systems used in hip and knee replacement, trauma and spine surgeries as well as hip, knee and shoulder implants. Additionally, Greatbatch Medical offers value-added assembly and design engineering services for medical systems and devices within the markets in which it operates.

Electrochem provides technology solutions for critical industrial applications, including customized battery power and wireless sensing systems. Originating from the lithium cell invented for the implantable pacemaker by our Company’s founder, Wilson Greatbatch, Electrochem’s technology and superior quality and reliability is utilized in markets world-wide.

### Our Customers

Greatbatch Medical customers include leading OEMs, in alphabetical order here and throughout this report, such as Biotronik, Boston Scientific, DePuy, Johnson & Johnson, Medtronic, Smith & Nephew, Sorin Group, St. Jude Medical, Stryker and Zimmer. The nature and extent of our selling relationships with each OEM varies in terms of breadth of products purchased, purchased product volumes, length of contractual commitment, ordering patterns, inventory management and selling prices. During the first three months of 2010, Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical collectively accounted for 63% of our total sales.

The initial term of our supply agreement with Boston Scientific pursuant to which Boston Scientific purchases a certain percentage of the batteries, capacitors, filtered feedthroughs and case halves it uses in its IMDs ends on December 31, 2010. The agreement may be renewed for one or more four-year renewal terms upon mutual agreement of the parties. We are actively negotiating a follow-on agreement with targeted completion during 2010.

Our Electrochem customers are primarily companies in markets such as energy, security, portable medical and environmental monitoring including 3M, General Electric, Halliburton, Honeywell, Thales, Weatherford and Zoll Medical.

\- 23 -

### Financial Overview

Sales for the first quarter of 2010 were $132.0 million compared to $139.8 million in the comparable 2009 period and $125.8 million for the fourth quarter of 2009. The 6% decline from the prior year was due to inventory stocking by our customers in the 2009 period and the uncertain economic and regulatory environment, which primarily impacted our orthopaedics and energy markets. However, in comparison to the sequential 2009 fourth quarter, sales increased 5% driven by improvements across all of our product lines, including a 17% increase in orthopaedics and an 8% increase in vascular sales. Our sequential growth was broad-based and was supported by improvement in all of the underlying markets we serve and is a positive sign that those markets have begun to stabilize.

We prepare our consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”). Additionally, we consistently report and discuss in our quarterly earnings releases and investor presentations adjusted operating income and margin, adjusted net income and adjusted earnings per diluted share. These adjusted amounts consist of GAAP amounts excluding the following adjustments to the extent they occur during the period: (i) acquisition-related charges; (ii) facility consolidation; manufacturing transfer and system integration charges; (iii) asset write-down and disposition charges; (iv) litigation charges; (v) the impact of accounting changes and (vi) the income tax (benefit) related to these adjustments. We believe that reporting these amounts provides important supplemental information to our investors and creditors seeking to understand the financial and business trends relating to our financial condition and results of operations. Additionally, the performance-based compensation of our executive management is determined utilizing these adjusted amounts.

GAAP operating income for the first quarter of 2010 was $14.0 million, or 10.6% of sales, compared to $14.8 million, or 10.6% of sales, for the 2009 first quarter. Similarly, adjusted operating income was $15.0 million, or 11.4% of sales, in the first quarter 2010, compared to $17.6 million, or 12.6% of sales, for the comparable 2009 period. The decrease in GAAP and adjusted operating income from the prior year was mainly due to lower revenue levels, as described above, as well as a higher level of net research, development and engineering costs (“RD&E”), which, as expected, were higher in the current year period due to further investment in the development of new technologies in order to create long-term growth opportunities, as well as a lower level of customer cost reimbursements. The negative impact of these variances was partially offset by a lower level of selling, general and administrative expenses (“SG&A”) due to our various consolidation and cost cutting initiatives, as well as reduced 2010 performance-based compensation of approximately $1.6 million for the quarter compared to the 2009 period.

A reconciliation of GAAP operating income to adjusted operating income is as follows (in thousands):

|  | Three months ended April 2, 2010 | April 3, 2009 |
| --- | ---: | ---: |
| Operating income as reported: | $13,996 | $14,799 |
| Adjustments: |  |  |
| Consolidation costs | 320 | 1,899 |
| Integration expenses | 122 | 863 |
| Asset dispositions & other | 550 | 41 |
| Operating income — adjusted | $14,988 | $17,602 |
| Operating margin — adjusted | 11.4% | 12.6% |

This lower operating income, as well as a higher effective tax rate in 2010, due to the expiration of the U.S. R&D tax credit at the end of 2009, caused GAAP diluted EPS for the first quarter 2010 to decrease to $0.24 per share compared to $0.28 per share for the first quarter 2009. Similarly, adjusted diluted EPS were $0.32 per share in the first quarter 2010 versus $0.41 for the comparable 2009 period.

\- 24 -

A reconciliation of GAAP income before taxes to adjusted net income and adjusted diluted EPS is as follows (in thousands, except per share amounts):

|  | Three months ended April 2, 2010 | April 3, 2009 |
| --- | ---: | ---: |
| Income before taxes as reported: | $8,534 | $9,728 |
| Adjustments: |  |  |
| Consolidation costs | 320 | 1,899 |
| Integration expenses | 122 | 863 |
| Asset dispositions & other | 550 | 41 |
| Adjusted income before taxes | 9,526 | 12,531 |
| Incremental non-cash interest expense on CSN II convertible debt (Note 5) | 1,914 | 1,775 |
| Sub-total | 11,440 | 14,306 |
| Adjusted provision for income taxes | 4,004 | 4,666 |
| Adjusted net income | $7,436 | $9,640 |
| Adjusted diluted EPS | $0.32 | $0.41 |
| Number of shares | 23,900 | 23,900 |

Cash flows from operations for the first quarter of 2010 were $21.2 million compared to $0.06 million for the 2009 first quarter and $21.5 million for the 2009 fourth quarter. The increase from the prior year first quarter is primarily due to our strategic initiatives designed to improve operational efficiency, which included initiatives to reduce inventory and receivable levels, as well as the timing of payments and lower consolidation and integrations costs. As of April 2, 2010, we had $56.3 million of cash and cash equivalents and $114 million of availability under our revolving line of credit. We currently expect that cash generated during 2010 will be used to support capital expenditures and to pay down debt.

### Our CEO’s View

We carried the momentum that began in the fourth quarter of last year into 2010, delivering sequential sales growth for the second consecutive quarter. More importantly, our growth was broad-based and was supported by improvement in all of the underlying markets we serve. We are encouraged by this top-line growth and have reiterated our annual sales growth targets for the year.

During the quarter, we continued to take steps to improve our operating efficiency in order to fund our RD&E investments and we expect our operating margin to improve throughout the remainder of the year as sales increase and we further leverage our manufacturing capacity. We remain confident that our full-year adjusted operating margin will be in-line with our target of 12.0% to 13.5% of sales for 2010. Additionally, we remain committed to our long-term growth and profitability, which we believe will be fueled by our investments in innovative new products and solutions, as well as improved operational efficiencies across our business.

### Government Regulation

In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively “Health Care Reform”) legislating broad-based changes to the U.S. health care system. Health Care Reform could significantly impact our business operations and financial results, including higher or lower revenue, as well as higher employee medical costs and taxes. Many significant parts of the legislation will be phased in over the next eight years and require further guidance and clarification in the form of regulations. As a result, many of the impacts of Health Care Reform will not be known until those regulations are enacted, which we expect to occur over the next several years.

\- 25 -

### Product Development

Currently, we are developing a series of new products for customer applications in the CRM, neuromodulation, vascular, orthopaedics and Electrochem markets. Some of the key development initiatives include:

1\. To continue to develop complete system solutions for our OEM customers in the markets we operate in;

2\. To continue the evolution of our Q batteries;

3\. To continue development of MRI compatible leadwires and other neuromodulation products;

4\. To continue development of higher energy/higher density capacitors;

5\. To integrate Biomimetic coating technology with our therapy delivery devices;

6\. To complete the design of next generation steerable catheters and introducers;

7\. To further develop minimally invasive surgical techniques for the orthopaedics industry;

8\. To develop disposable instrumentation for the orthopaedics industry;

9\. To provide wireless sensing solutions to Electrochem customers; and

10\. To develop a charging platform for Electrochem’s secondary offering.

As a result of the investments we have made over the last two years, we are now in a position to provide our OEM customers with full “system” solutions. This includes providing comprehensive products and services, from development and regulatory submissions through manufacturing and supporting worldwide distribution. These systems are niche product solutions that complement our OEM customers’ products and utilize our expertise and capabilities. This strategy includes partnering with our OEM customers, including sharing technology and resources, in order to bring these solutions to market. The benefits to our OEM customers include shortening the time to market for these products by accelerating the velocity of innovation, optimizing their supply chain and ultimately providing them with cost efficiencies.

As previously disclosed, on March 15, 2010 Greatbatch Medical received clearance from the U.S. Food and Drug Administration for its OptiSeal™ Valved PTFE Peelable Introducer. We have also received approval in Canada and OptiSeal™ is CE marked for distribution in Europe. OptiSeal™ represents the first 510(k) regulatory clearance received under the Greatbatch Medical brand and is a result of the significant investments made over the last few years.

OptiSeal™ represents the type of niche “system” level products that we are trying to provide. That is, products that are complementary to the core products of our customers and utilize our expertise and capabilities. OptiSeal™ was developed in collaboration with our OEM customers, leverages our technology and provides our customers with value-added innovative features.

The market opportunity for the OptiSeal™ project is $10 — $20 million. Additionally, it provides us with an opportunity for expansion into the vascular and peripheral access markets. In the second half of this year we expect to finalize distribution agreements with our customers and OptiSeal™ will begin to provide a return on the R&D investment we have made over the last two years. We also expect to make additional announcements similar to OptiSeal™ over the next several years as more of these “system” level projects are commercialized.

### Cost Savings and Consolidation Efforts

In the first quarter of 2010 and 2009, we recorded charges in other operating expenses related to our ongoing cost savings and consolidation efforts. Additional information regarding the timing, cash flow and amount of future expenditures is set forth in Note 8 — “Other Operating Expenses, Net” of the Notes to the Condensed Consolidated Financial Statements contained in this report.

### Our Financial Results

We utilize a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. For 52-week years, each quarter contains 13 weeks. The first quarter of 2010 and 2009 ended on April 2, and April 3, respectively. The commentary that follows should be read in conjunction with our Condensed Consolidated Financial Statements and related notes and with the Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Form 10-K for the fiscal year ended January 1, 2010.

\- 26 -

The following table presents certain selected condensed consolidated financial statement information for the periods presented:

*In thousands, except per share data*

| Greatbatch Medical | Three months ended April 2, 2010 | April 3, 2009 | $% Change | Change |
| --- | ---: | ---: | ---: | ---: |
| CRM/Neuromodulation | $76,925 | $77,267 | $(342) | 0% |
| Vascular | 8,166 | 10,733 | (2,567) | -24% |
| Orthopaedics | 29,442 | 34,083 | (4,641) | -14% |
| Total Greatbatch Medical | 114,533 | 122,083 | (7,550) | -6% |
| Electrochem | 17,496 | 17,735 | (239) | -1% |
| Total sales | 132,029 | 139,818 | (7,789) | -6% |
| Cost of sales | 90,365 | 95,654 | (5,289) | -6% |
| Gross profit | 41,664 | 44,164 | (2,500) | -6% |
| Gross profit as a % of sales | 31.6% | 31.6% |  | 0.0% |
| SG&A | 15,652 | 18,687 | (3,035) | -16% |
| SG&A as a % of sales | 11.9% | 13.4% |  | -1.5% |
| RD&E, net | 11,024 | 7,875 | 3,149 | 40% |
| RD&E, net as a % of sales | 8.3% | 5.6% |  | 2.7% |
| Other operating expenses, net | 992 | 2,803 | (1,811) | -65% |
| Operating income | 13,996 | 14,799 | (803) | -5% |
| Operating margin | 10.6% | 10.6% |  | 0.0% |
| Interest expense | 5,148 | 4,889 | 259 | 5% |
| Interest income | (2) | (25) | 23 | -92% |
| Other expense, net | 316 | 207 | 109 | 53% |
| Provision for income taxes | 2,987 | 3,064 | (77) | -3% |
| Effective tax rate | 35.0% | 31.5% |  | 3.5% |
| Net income | $5,547 | $6,664 | $(1,117) | -17% |
| Net margin | 4.2% | 4.8% |  | -0.6% |
| Diluted earnings per share | $0.24 | $0.28 | $(0.04) | -14% |

### Sales (Dollars in thousands)

| Product Lines Greatbatch Medical | Three months ended April 2, 2010 | April 3,% 2009 | Change | January 1,% 2010 | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| CRM/Neuromodulation | $76,925 | $77,267 | 0% | $75,969 | 1% |
| Vascular | 8,166 | 10,733 | -24% | 7,556 | 8% |
| Orthopaedics | 29,442 | 34,083 | -14% | 25,233 | 17% |
| Total Greatbatch Medical | 114,533 | 122,083 | -6% | 108,758 | 5% |
| Electrochem | 17,496 | 17,735 | -1% | 17,050 | 3% |
| Total Sales | $132,029 | $139,818 | -6% | $125,808 | 5% |

\- 27 -

***Greatbatch Medical —*** The nature and extent of our selling relationship with each OEM customer is different in terms of component products purchased, selling prices, product volumes, ordering patterns and inventory management. For customers with long-term contracts, we have negotiated fixed pricing arrangements for pre-determined volume levels with pricing fixed within each level. In general, the higher the volume level, the lower the pricing. We have pricing arrangements with our customers that at times do not specify minimum order quantities. We recognize revenue when it is realized or realizable and earned. This occurs when persuasive evidence of an arrangement exists, delivery has occurred, the price is fixed or determinable, the buyer is obligated to pay us (i.e., not contingent on a future event), the risk of loss is transferred, there is no obligation of future performance, collectability is reasonably assured and the amount of future returns can reasonably be estimated. Those criteria are met at the time of shipment when title passes.

Our visibility to customer ordering patterns is over a relatively short period of time. Our customers may have inventory management programs and alternate supply arrangements of which we are unaware. Additionally, the relative market share among the OEM manufacturers changes periodically. Consequently, these and other factors can significantly impact our sales in any given period. Our customers may initiate field actions with respect to market-released products. These actions may include product recalls or communications with a significant number of physicians about a product or labeling issue. The scope of such actions can range from very minor issues affecting a small number of units to more significant actions. There are a number of factors, both short-term and long-term, related to these field actions that may impact our results. In the short-term, if a product has to be replaced, or customer inventory levels have to be restored, component demand will increase. Also, changing customer order patterns due to market share shifts or accelerated device replacements may also have a positive or negative impact on our sales results in the near-term. These same factors may have longer-term implications as well. Customer inventory levels may ultimately have to be rebalanced to match new demand.

Greatbatch Medical sales decreased 6% for the first quarter 2010 when compared to the same 2009 period due to inventory stocking by customers in the 2009 period and the uncertain economic and regulatory environment, which primarily impacted our orthopaedics market.

CRM and neuromodulation sales remained consistent with the prior year first quarter. Current quarter sales includes the benefit of further adoption of the Company’s Q batteries, which empower new device features and reduce the overall size of medical devices, as well as increased assembly revenue due to customer market share shifts. Offsetting these increases was lower filtered feedthrough sales as the first quarter 2009 included the benefit of customer product launches and customer market share shifts.

First quarter 2010 sales for our vascular product line were $8.2 million, compared to prior year sales of $10.7 million. This decrease was primarily due to lower introducer sales as a result of customer inventory stocking during the first half of 2009 in connection with our on-going introducer litigation. The impact of this inventory stocking began to ease during the first quarter of 2010 as vascular sales increased 8% from the sequential quarter. We remain optimistic about the potential of this product line as we continue to work with customers on developing systems level products. However, many of the projects that we are currently working on will not begin to generate sales until the second half of 2010 and beyond.

Our orthopaedics product line sales were $29.4 million for the first quarter 2010 compared to $34.1 million for the same 2009 period. Similar to prior quarters, this decrease is due to the uncertain economic and regulatory environment, which caused reduced spending on elective procedures and increased emphasis on inventory management programs from our customers. As expected, the impact of these factors eased further during the current quarter as sales increased 17% over the sequential quarter. During this industry downturn, we continue to streamline and invest in our orthopaedics operations, which we believe present significant opportunities. Going forward, we expect year over year comparables to be more favorable for this product line.

\- 28 -

***Electrochem —*** First quarter 2010 sales for the Electrochem business segment were $17.5 million, slightly below the $17.7 million in the first quarter 2009. The decrease from the prior year primarily related to the slowdown in the energy and portable medical markets, which caused customers to reduce inventory levels and push back projects. These conditions continued to ease in the first quarter of 2010, but are still expected to be a challenge for the next two quarters.

***2010 Sales Outlook —*** At this time, we expect 2010 annual sales growth by product line to be as follows:

|  |  |
| --- | --- |
| • CRM & Neuromodulation | 2% to 5% |
| • Vascular | 3% to 7% |
| • Orthopaedics | 3% to 7% |
| • Electrochem | 0% to 5% |

Our 2010 sales growth outlook may be impacted by a variety of factors including, but not limited to, a further softening in the orthopaedics and Electrochem markets, potential delays in elective surgeries, the current financial market unrest, changes in exchange rates and Health Care Reform (See “Forward-Looking Statements”). Within the markets we serve, the orthopaedics market represents the least predictable market due to the elective nature of many of the surgeries and procedures in which our products are used. Additionally, recently enacted Health Care Reform, including the medical device innovation tax and expanded health care insurance coverage, could significantly impact our revenue. The extent to which Health Care Reform will impact our revenue, and whether that impact will be positive, negative or both, is not fully known at this time, and will not be fully known until further guidance and clarification, in the form of regulation, is issued.

### Gross Profit

Changes to gross profit as a percentage of sales from the prior year period were primarily due to the following:

|  | Three months ended April 2, 2010 |
| --- | ---: |
| Performance-based compensation (a) | 1.7% |
| Excess capacity (b) | -0.9% |
| Selling price (c) | -0.5% |
| Mix change (d) | -0.4% |
| Other | 0.1% |
| Total percentage point change to gross profit as a percentage of sales | 0.0% |

(a) Amount represents lower performance-based compensation, recorded based upon the results of the current quarter. Performance-based compensation for the remainder of 2010 is expected to increase as our revenue and operating results improve.

(b) Our gross profit percentage was negatively impacted from excess capacity costs driven by the lower volumes primarily for the orthopaedics product line. In accordance with our inventory accounting policy, excess capacity costs are expensed.

(c) Our gross profit percentage was negatively impacted due to contractual volume price reductions and price concessions made to our larger OEM customers on certain product lines. We expect this pricing pressure to continue in the future.

(d) Our gross profit percentage was negatively impacted from a decrease in sales of higher margin products, mainly filtered feedthroughs, as a percentage of total sales.

We expect our gross profit as a percentage of sales to increase for the remainder of 2010 and over the next several years as sales levels increase and we further leverage our manufacturing capacity. Additionally, further consolidation and new product introductions, resulting from current research and development efforts, are expected to help drive gross margin expansion.

\- 29 -

### SG&A Expenses

Changes to SG&A expenses from the prior year period were due to the following (in thousands):

|  | Change from prior year Three months |
| --- | ---: |
| Performance-based compensation (a) | $(1,645) |
| Allowance for doubtful accounts (b) | (952) |
| Other | (438) |
| Net decrease in SG&A | $(3,035) |

(a) Amount represents lower performance-based compensation, recorded based upon the results of the current quarter, compared to the 2009 period. Performance-based compensation for the remainder of 2010 is expected to increase as our revenue and operating results improve.

(b) Amounts primarily relate to lower losses incurred on uncollectible receivables compared to the 2009 period, which included higher Electrochem and orthopaedics write-offs due to the economic slowdown.

Throughout the remainder of 2010, we expect SG&A expenses to increase slightly from the current levels due to normal inflationary cost increases, investment in sales and marketing and higher performance-based compensation as our revenue and operating results improve.

### RD&E Expenses, Net

Net RD&E costs are as follows (in thousands):

|  | Three months ended April 2, 2010 | April 3, 2009 |
| --- | ---: | ---: |
| Research and development costs | $4,528 | $4,501 |
| Engineering costs | 8,013 | 5,956 |
| Less cost reimbursements | (1,517) | (2,582) |
| Engineering costs, net | 6,496 | 3,374 |
| Total research and development and engineering costs, net | $11,024 | $7,875 |

As expected, net RD&E expenses for the 2010 first quarter of $11.0 million were above the comparable 2009 period of $7.9 million, due to further investment in the development of new technologies. Additionally, during the quarter we received a lower level of customer cost reimbursements. These cost reimbursements can vary significantly from period to period due to the timing of the achievement of milestones on development projects. Excluding these customer cost reimbursements, RD&E was 9.5% of sales for the current quarter compared to 7.5% of sales in the first quarter of 2009. We anticipate that, while cost reimbursements will return to more normal levels, the higher level of RD&E investment will continue for the remainder of 2010, consistent with our long-term growth strategy. Our long-term growth strategy includes investing resources in new technologies, including system level solutions for our customers. This strategy also includes partnering with our OEM customers, including sharing technology and resources, in order to bring these solutions to market. The benefits to our OEM customers is that it will shorten their time to market by accelerating the velocity of innovation, optimizing their supply chain and ultimately providing them with cost efficiencies. As mentioned previously, OptiSealTM is one example of these system level projects. The timeline for approval of our vascular market systems projects is shorter than for our other markets. We anticipate making announcements similar to OptiSealTM in the next several quarters.

\- 30 -

### Other Operating Expenses, Net

Other operating expenses, net are comprised of the following costs (in thousands):

|  | Three months ended April 2, 2010 | April 3, 2009 |
| --- | ---: | ---: |
| (a) 2007 & 2008 facility shutdowns and consolidations | $320 | $1,899 |
| (b) Integration costs | 122 | 863 |
| (c) Asset dispositions and other | 550 | 41 |
|  | $992 | $2,803 |

(a) Refer to “Cost Savings and Consolidation Efforts.” We have completed all of our publicly announced consolidation initiatives. However, we continually analyze our business to find ways to improve our operational efficiency and we expect to take additional steps to drive further improvements, particularly with respect to our orthopaedics product line.

(b) For the first quarter of 2010 and 2009, we incurred costs related to the integration of the companies acquired in 2007 and 2008. The integration initiatives include the implementation of the Oracle ERP system, training and compliance with policies, as well as the implementation of lean manufacturing and six sigma initiatives. The expenses are primarily for consultants, relocation and travel costs that will not be required after the integrations are completed.

(c) During the first quarter of 2010 and 2009, the Company recorded write-downs in connection with various asset disposals.

In 2010, consolidation and integration expenses are expected to be approximately $4 million to $6 million.

### Interest Expense and Interest Income

Interest expense and interest income for the first quarter of 2010 were consistent with the same periods of 2009. Going forward, we expect interest expense to remain at current levels as the benefit of paying down our long-term debt with excess cash flow from operations is expected to be offset by increased discount amortization and interest expense associated with the Electrochem Litigation appeal (See “Litigation”).

### Other Expense, Net

Other expense, net primarily includes the impact of foreign currency exchange rate fluctuations on transactions denominated in foreign currencies, which did not materially impact our results in the first quarter of 2010 or 2009. The Company generally does not expect foreign currency exchange rate fluctuations to have a material impact on its net income.

### Provision for Income Taxes

The effective tax rate for the first quarter of 2010 was 35.0% compared to 31.5% for the first quarter of 2009. The current period rate reflects a tax benefit from having operations outside the U.S., which are taxed at rates lower than the U.S. statutory rate of 35%. This benefit was offset by the impact of non-deductible items and the absence of the research & development tax credit, which expired at the end of 2009. Pending legislation would retroactively reinstate the R&D tax credit to the beginning of 2010. This legislation, if enacted, would positively impact the effective tax rate in the period that it is enacted.

We believe that it is reasonably possible that a reduction of approximately $0.7 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of the expiration of applicable statutes of limitation, which would positively impact our effective tax rate in the period of reduction.

\- 31 -

### Liquidity and Capital Resources

*(Dollars in millions)*

|  | April 2, 2010 | January 1, 2010 |
| --- | ---: | ---: |
| Cash and cash equivalents(a) | $56.3 | $37.9 |
| Working capital (a) | $138.2 | $119.9 |
| Current ratio (a) | 2.1:1.0 | 1.9:1.0 |

(a) These increases primarily relate to the cash flow generated from operations of $21.2 million for the first quarter of 2010 partially offset by net expenditures for property, plant and equipment of $2.0 million. The increase in cash flow from operations over the prior year first quarter is primarily due to our strategic initiatives designed to improve operational efficiency including initiatives to reduce inventory and receivable levels. Additionally, our cash flow from operations was higher than the prior year due to the timing of payments and lower consolidation and integrations costs.

***Revolving Line of Credit —*** We have a senior credit facility (the “Credit Facility”) consisting of a $235 million revolving line of credit, which can be increased to $335 million upon our request and approval by a majority of the lenders. The Credit Facility also contains a $15 million letter of credit subfacility and a $15 million swingline subfacility. In connection with the Electrochem Litigation we were required to bond the amount of the judgment and statutory interest in order to appeal. We satisfied this requirement by posting a bond, which required collateralization. We received approval from the lenders supporting our Credit Facility to increase the letter of credit subfacility by $35 million for use only in connection with bonding the appeal of the Electrochem Litigation. The Credit Facility is secured by our non-realty assets including cash, accounts and notes receivable, and inventories, and has an expiration date of May 22, 2012 with a one-time option to extend to April 1, 2013 if no default has occurred.

The Credit Facility is supported by a consortium of six banks with no bank controlling more than 25% of the facility. As of April 2, 2010, each bank supporting the Credit Facility has an S&P credit rating of at least BBB- or better, which is considered investment grade.

Interest rates under the Credit Facility are, at our option, based upon the current prime rate or the LIBOR rate plus a margin that varies with our leverage ratio. If interest is paid based upon the prime rate, the applicable margin is between minus 1.25% and 0.00%. If interest is paid based upon the LIBOR rate, the applicable margin is between 1.00% and 2.00%. We are also required to pay a fee on our outstanding letter of credit equal to a margin between 1.00% and 2.00%, depending on our leverage ratio, plus 0.125%. We are also required to pay a commitment fee between 0.125% and 0.250% per annum on the unused portion of the Credit Facility based on our leverage ratio.

The weighted average interest rate on borrowings under our revolving line of credit as of April 2, 2010, which does not include the impact of the interest rate swaps, was 1.43% and resets based upon the six-month LIBOR rate. As of April 2, 2010, we had $114 million available under the Credit Facility. This amount may vary from period to period based upon our debt and EBITDA levels, which impacts the covenant calculations. The interest rate on the $23 million letter of credit outstanding as of April 2, 2010 was 1.125%.

The Credit Facility contains limitations on the incurrence of indebtedness, limitations on the incurrence of liens and licensing of intellectual property, limitations on investments and restrictions on certain payments. Except to the extent paid by the issuance of common stock of Greatbatch or paid out of cash on hand, the Credit Facility limits the amount paid for acquisitions in total to $100 million. The restrictions on payments, among other things, limits repurchase of our stock to $60 million and limit the ability of the Company to make cash payments upon conversion of CSN II. These limitations can be waived upon the Company’s request and approval of a simple majority of the lenders.

\- 32 -

The Credit Facility requires us to maintain a ratio of adjusted EBITDA, as defined in the credit agreement, to interest expense of at least 3.00 to 1.00. For the twelve month period ending April 2, 2010, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our credit agreement, was 9.0 to 1.00, well above the required limit. The Credit Facility also requires us to maintain a total leverage ratio, as defined in the credit agreement, of not greater than 4.50 to 1.00. As of April 2, 2010 our total leverage ratio, calculated in accordance with our credit agreement, was 3.35 to 1.00, well below the required limit. The calculation of adjusted EBITDA and leverage ratio exclude non-cash charges, as well as charges in connection with the Electrochem Litigation up to a limit of $35 million.

The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable.

Based upon our current capital needs, we anticipate utilizing free cash flow (cash flow from operations less capital expenditures) to make principal payments on our long-term debt.

***Operating activities —*** Cash flows from operations for the first quarter of 2010 were $21.2 million compared to $0.06 million for the 2009 first quarter and $21.5 million for the 2009 fourth quarter. The increase from the prior year first quarter is primarily due to the our strategic initiatives designed to improve operational efficiency, which included initiatives to reduce inventory and receivable levels, as well as the timing of payments and lower consolidation and integrations costs. We anticipate that cash on hand along with cash flow from operations and availability under our revolving line of credit will be sufficient to meet our operating (including any potential legal settlements) needs.

***Investing activities —*** Net cash used in investing activities for the first three months of 2010 were $2.0 million and was primarily related to maintenance capital expenditures. Our current expectation is that capital spending for the remainder of 2010 will be in the range of $20 million to $30 million, of which approximately half is discretionary in nature. These purchases relate to routine investments to support our internal growth, as well as additional investment in our orthopaedics business in order to further drive improvements and growth including the purchase of rapid prototyping equipment for our new orthopaedics design center opened in February 2010.

We anticipate that cash on hand along with cash flow from operations and availability under our revolving line of credit will be sufficient to fund these capital expenditures. We regularly engage in discussions relating to potential acquisitions. Going forward, we will continue to consider strategically targeted and opportunistic acquisitions.

***Financing activities —*** Net cash used in financing activities for the 2010 first quarter were $0.6 million. As of April 2, 2010, we have outstanding $30.5 million of CSN I, which contain a put option exercisable on June 15, 2010 and is classified as a current liability. We currently expect to repay this current portion of long-term debt, and the associated deferred tax liability of $6.2 million in June 2010 with cash on hand, which totaled $56.3 million as of April 2, 2010. After June 2010, we expect excess cash flow to be used to pay down amounts outstanding under our revolving line of credit. We continually assess our financing facilities and capital structure to ensure liquidity and capital levels are sufficient to meet our strategic objectives. In the future, we may adjust our capital structure as funding opportunities present themselves.

***Capital Structure —*** As of April 2, 2010, our capital structure consisted of $228.2 million of convertible subordinated notes, $98.0 million of debt under our revolving line of credit and 23.2 million shares of common stock outstanding. Additionally, we had $56.3 million in cash and cash equivalents, which is sufficient to meet our short-term operating cash needs. If necessary, we have access to $114 million under our available line of credit and are authorized to issue 100 million shares of common stock and 100 million shares of preferred stock. The market value of our outstanding common stock since our initial public offering has exceeded our book value; accordingly, we believe that if needed we can access public markets to raise additional capital. Our capital structure allows us to support our internal growth and provides liquidity for corporate development initiatives.

\- 33 -

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Contractual Obligations

The following table summarizes our significant contractual obligations at April 2, 2010:

| CONTRACTUAL OBLIGATIONS | Payments due by period Total | Less than 1 year | 1-3 years | 3-5 years | More than 5 years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Debt obligations (a) | $355,347 | $43,025 | $112,315 | $200,007 | $— |
| Operating lease obligations (b) | 11,603 | 2,192 | 4,234 | 3,513 | 1,664 |
| Purchase obligations (b) | 12,771 | 12,265 | 506 | — | — |
| Foreign currency contracts (b) | 6,750 | 6,750 | — | — | — |
| Pension obligations (c) | 10,903 | 621 | 1,982 | 2,286 | 6,014 |
| Total | $397,374 | $64,853 | $119,037 | $205,806 | $7,678 |

(a) Includes the annual interest expense on our convertible debentures of 2.25%, which is paid semi-annually. These amounts assume the June 2010 put option is exercised on the $30.5 million of CSN I and we are required to pay the $6.2 million of deferred taxes related to these notes. Amounts also include the expected interest expense on the $98.0 million outstanding on our line of credit based upon the period end weighted average interest rate of 3.9%, which includes the impact of our interest rate swaps outstanding. See Note 5— “Debt” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our debt obligations.

(b) See Note 10 — “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our operating lease, purchase obligations and foreign currency contracts.

(c) See Note 6 — “Pension Plans” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about our pension plan obligations. These amounts do not include any potential future contributions to our pension plan that may be necessary if the rate of return earned on pension plan assets is not sufficient to fund the rate of increase of our pension liability. Future cash contributions may be required. As of January 1, 2010, the most recent valuation date, our actuarially determined pension benefit obligation exceeded the plans assets by $4.0 million.

This table does not reflect $3.4 million of unrecognized tax benefits as we are uncertain as to if or when such amounts may be settled. Refer to Note 9 — “Income Taxes” of the Notes to Condensed Consolidated Financial Statements in this report for additional information about these unrecognized tax benefits. Additionally, the table does not include any potential payments that may be due in connection with the Electrochem Litigation (See Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in this report).

In an attempt to help offset the cost of rising health care expenses, beginning in 2010, we began self-funding the medical insurance coverage for all of our U.S. based employees. Our risk is being limited through the use of stop loss insurance which has deductibles in the amount of $0.2 million per covered participant and $9.9 million in the aggregate per year. As of April 2, 2010, we have $2.2 million accrued related to the self-insurance of our medical plan, which is recorded as Accrued Expenses and Other Current Liabilities in the Condensed Consolidated Balance Sheet and is not included in the contractual obligations table above.

\- 34 -

### Litigation

We are party to various legal actions arising in the normal course of business. A complete list of all material pending legal actions against the company are set forth at Note 10 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements contained in this report. Except for the items set forth in Note 10, we do not believe that the ultimate resolution of any pending legal actions will have a material adverse effect on our consolidated results of operations, financial position or cash flows. However, litigation is subject to inherent uncertainties. If an unfavorable ruling were to occur, there exists the possibility of a material adverse impact in the period in which the ruling occurs.

### Inflation

We utilize certain critical raw materials (including precious metals) in our products that we obtain from a limited number of suppliers due to the technically challenging requirements of the supplied product and/or the lengthy process required to qualify these materials with our customers. We cannot quickly establish additional or replacement suppliers for these materials because of these requirements. Our results may be negatively impacted by an increase in the price of these critical raw materials. This risk is partially mitigated as many of the supply agreements with our customers allow us to partially adjust prices for the impact of any raw material price increases and the supply agreements with our vendors have final one-time buy clauses to meet a long-term need. Historically, raw material price increases have not materially impacted our results of operations.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), American Institute of Certified Public Accountants (“AICPA”) or other authoritative accounting body to determine the potential impact they may have on our Consolidated Financial Statements. Based upon this review, we do not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Consolidated Financial Statements.

### Application of Critical Accounting Estimates

Our unaudited Condensed Consolidated Financial Statements are based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make significant assumptions. We believe that some of the more critical estimates and related assumptions that affect our financial condition and results of operations are in the areas of the valuation of goodwill, other identifiable intangible assets, stock-based compensation, inventories, tangible long-lived assets and the provision for income taxes. For further information, refer to Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Item 8 “Financial Statements and Supplementary Data” in our Annual Report on Form 10-K for the year ended January 1, 2010. During the three months ended April 2, 2010, we did not change or adopt any new accounting policies that had a material effect on our Consolidated Financial Statements.

### Forward-Looking Statements

Some of the statements contained in this Quarterly Report on Form 10-Q and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, which are subject to known and unknown risks, uncertainties and assumptions. They include statements relating to:

- future sales, expenses and profitability;
- the future development and expected growth of our business and the markets we operate in;
- our ability to successfully execute our business model and our business strategy;
- our ability to identify trends within the implantable medical devices, medical components, and Electrochem markets and to offer products and services that meet the changing needs of those markets;
- projected capital expenditures; and
- trends in government regulation.

\- 35 -

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those suggested by these forward-looking statements. In evaluating these statements and our prospects generally, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We are under no duty to update any of the forward-looking statements after the date of this report or to conform these statements to actual results.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: dependence upon a limited number of customers, product obsolescence, inability to market current or future products, pricing pressure from customers, reliance on third party suppliers for raw materials, products and subcomponents, fluctuating operating results, inability to maintain high quality standards for our products, challenges to our intellectual property rights, product liability claims, inability to successfully consummate and integrate acquisitions, unsuccessful expansion into new markets, competition, inability to obtain licenses to key technology, regulatory changes or consolidation in the healthcare industry, and other risks and uncertainties that arise from time to time as described in the Company’s Annual Report on Form 10-K and other periodic filings with the Securities and Exchange Commission.

## Market risk

As filed, 5,604 characters.

***Foreign Currency —*** We have significant foreign operations in France, Mexico and Switzerland, which expose the Company to foreign currency exchange rate fluctuations due to transactions denominated in Euros, Pesos and Swiss Francs, respectively. We continuously evaluate our foreign currency risk and will take action from time to time in order to best mitigate these risks, which includes the use of various derivative instruments such as forward currency exchange contracts. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency exposures would have had an impact of approximately $8 million on our annual sales. This amount is not indicative of the hypothetical net earnings impact due to partially offsetting impacts on cost of sales and operating expenses in those currencies.

In February 2009, we entered into forward contracts to purchase 10 million Mexican pesos per month from March 2009 to December 2009 at an exchange rate of 14.85 pesos per one U.S. dollar. These contracts were entered into in order to hedge the risk of peso-denominated payments associated with the operations at our Tijuana, Mexico facility for 2009. These contracts were accounted for as cash flow hedges. No portion of the changes in fair value of the foreign currency contracts during the first three months of 2009 was considered ineffective.

In December 2009, we entered into forward contracts to purchase 6.6 million Mexican pesos per month from January 2010 to December 2010 at an exchange rate of 13.159 pesos per one U.S. dollar. In February 2010, we entered into forward contracts to purchase an additional 3.3 million Mexican pesos per month from February 2010 to December 2010 at an exchange rate of 13.1595 pesos per one U.S. dollar. These contracts were entered into in order to hedge the risk of peso-denominated payments associated with the operations at our Tijuana, Mexico facility for 2010 and are being accounted for as cash flow hedges. As of April 2, 2010 these contracts had a positive fair value of $0.4 million, which is recorded within Other Current Assets in the Condensed Consolidated Balance Sheet. The amount recorded as a reduction of Cost of Sales during the first three months of 2010 related to these forward contracts was $0.2 million. No portion of the change in fair value of these foreign currency contracts during the first three months of 2010 was considered ineffective.

We translate all assets and liabilities of our foreign operations, where the U.S. dollar is not the functional currency, at the period-end exchange rate and translate sales and expenses at the average exchange rates in effect during the period. The net effect of these translation adjustments is recorded in the Condensed Consolidated Financial Statements as Comprehensive Income (Loss). The cumulative translation adjustment as of April 2, 2010 was a $1.1 million gain. Translation adjustments are not adjusted for income taxes as they relate to permanent investments in our foreign subsidiaries. Net foreign currency transaction gains and losses included in Other Expense, Net amounted to a gain of $0.3 million and a loss of $0.2 million for the first quarter of 2010 and 2009, respectively. A hypothetical 10% change in the value of the U.S. dollar in relation to our most significant foreign currency net assets would have had an impact of approximately $9 million on our foreign net assets as of April 2, 2010.

\- 36 -

***Interest Rate Swaps —*** As of April 2, 2010, we had $98 million outstanding on our revolving line of credit. Interest rates reset on this debt based upon the six-month LIBOR rate, thus subjecting us to interest rate risk. During 2008, we entered into three receive floating-pay fixed interest rate swaps indexed to the six-month LIBOR rate. The objective of these swaps is to hedge against potential changes in cash flows on our outstanding revolving line of credit. No credit risk was hedged. The receive variable leg of the swaps and the variable rate paid on the revolving line of credit bear the same rate of interest, excluding the credit spread, and reset and pay interest on the same dates.

Information regarding our outstanding interest rate swaps is as follows:

*(In thousands)*

*(In thousands)*

| Instrument | Type of hedge | Notional amount | Start date | End date | Pay fixed rate | Current receive floating rate | Fair value April 2, 2010 | Balance sheet location |
| --- | --- | ---: | --- | --- | ---: | ---: | ---: | --- |
| Int. rate swap | Cash flow | $80,000 | 3/5/2008 | 7/7/2010 | 3.09% | 1.08% | $(565) | Other Current Liabilities |
| Int. rate swap | Cash flow | 18,000 | 12/18/2008 | 12/18/2010 | 2.00% | 0.45% | (585) | Other Current Liabilities |
| Int. rate swap | Cash flow | 50,000 | 7/7/2010 | 7/7/2011 | 2.16% | 6M LIBOR | (187) | Other Long-Term Liabilities |
|  |  |  |  |  |  |  | $(1,337) |  |

The estimated fair value of the interest rate swap agreements represents the amount we would have to pay to terminate the contracts. No portion of the change in fair value of the interest rate swaps during the first quarters of 2010 or 2009 was considered ineffective. The amount recorded as additional Interest Expense related to the interest rate swaps was $0.6 million and $0.2 million during the first quarters of 2010 and 2009, respectively.

Any change in the LIBOR interest rate would not have an impact on our interest expense relating to the $98 million of floating rate revolving line of credit debt outstanding due to the interest rate swap agreements we have in place.

## Controls and procedures

As filed, 1,388 characters.

a. Evaluation of Disclosure Controls and Procedures.

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the SEC as of April 2, 2010. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by other of our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the SEC’s rules and forms. Based on their evaluation, as of April 2, 2010, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

\- 37 - b. Changes in Internal Control Over Financial Reporting.

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter to which this Quarterly Report on Form 10-Q relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 138 characters.

There have been no material changes in risk factors as previously disclosed in the Company’s Form 10-K for the year ended January 1, 2010.

Filed May 12, 2010.
Source: SEC EDGAR, the filing index for accession 0000950123-10-048285. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
